Asset Details
Do you wish to reserve the book?
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Do you wish to request the book?
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
2012
Overview
Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels in cerebrospinal fluid inversely correlated to psychotic symptoms. Furthermore, enhanced anandamide signaling let to a lower transition rate from initial prodromal states into frank psychosis as well as postponed transition. In our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol vs amisulpride, a potent antipsychotic, in acute schizophrenia to evaluate the clinical relevance of our initial findings. Either treatment was safe and led to significant clinical improvement, but cannabidiol displayed a markedly superior side-effect profile. Moreover, cannabidiol treatment was accompanied by a significant increase in serum anandamide levels, which was significantly associated with clinical improvement. The results suggest that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ Antipsychotic Agents - therapeutic use
/ Arachidonic Acids - physiology
/ Cannabidiol - therapeutic use
/ Endocannabinoids - physiology
/ Female
/ Humans
/ Male
/ Medicine
/ Original
/ Polyunsaturated Alkamides - blood
/ Psychiatric Status Rating Scales
/ Schizophrenia - drug therapy
/ Schizophrenia - physiopathology
/ Signal Transduction - drug effects
/ Signal Transduction - physiology
